Phase I clinical trial of 64Cu-ATSM for malignant brain tumors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.
CSF-ctDNA was detected in 59% of cases and showed high concordance (84%) with tumor mutations. Lower variant allelic frequency in CSF-ctDNA was associated with significantly worse survival outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results